Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease.
Participation consists in taking one or several blood samples depending on the group patients/controls.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Horton's disease |
| ||
| Infectious disease |
| ||
| Neoplasia |
| ||
| Control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 1 blood sample | Other |
| ||
| 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse) |
| Measure | Description | Time Frame |
|---|---|---|
| Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum | Up to 6 months | |
| Quantification of LTh17 by flow cytometry | Up to 6 months | |
| Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA | Up to 6 months | |
| Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations | Up to 6 months |
Not provided
Not provided
Inclusion Criteria:
Patients
Patients with Horton' s disease :
Patients with an infectious disease :
Patients with neoplasia ( solid tumour or hemopathy ) :
Controls :
These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP < 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex.
Exclusion Criteria :
Not provided
Not provided
Patients with Horton' s disease Patients with an infectious disease Patients with neoplasia ( solid tumor or hemopathy ) Healthy controls
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de BESANCON | Besançon | 25000 | France | |||
| CHU de DIJON |
Not provided
Not provided
Not provided
Not provided
| Other |
|
| Dijon |
| 21079 |
| France |
| CH de METZ | Metz | 57000 | France |
| ID | Term |
|---|---|
| D013700 | Giant Cell Arteritis |
| D003141 | Communicable Diseases |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D020293 | Vasculitis, Central Nervous System |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001167 | Arteritis |
| D014657 | Vasculitis |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided